WIT Pharma
All insights
Regulatory11 November 2026 · 6 min read

The VED list commission on 10 November: none of three, the start of the 2028 cycle and where the 2027 list stands

On 10 November the Ministry of Health commission reviewed three applications and backed none: two antiretrovirals were turned down on formal grounds, and the application for a haemophilia A product was not supported either. We set out what is known before the minutes are published, why the November session opens the 2028 list cycle and where the 2027 list stands.

On 10 November 2026 the Russian Ministry of Health commission responsible for the drug lists reviewed three applications for the Vital and Essential Drugs (VED) list and backed none of them. The minutes had not been published as of the date of this review (11 November 2026), so the vote counts and the wording of the grounds are given not from the primary source but from the Ministry's agenda and the reports of trade media that followed the session. The review will be updated once the minutes are out.

What was on the agenda

The Ministry published the agenda on 28 October: efanesoctocog alfa (Altuvoct, Sobi; haemophilia A) for the VED list and the 14 High-Cost Nosologies programme, and cabotegravir and rilpivirine (HIV infection) for the VED list. Only one proposal passed the documentary review of third-quarter applications - efanesoctocog alfa (results published on 20 October). Cabotegravir and rilpivirine were carried over from the second-quarter list: they had passed the documentary review in the summer but did not reach the August agenda. According to Vademecum, Pharmvestnik and GxP News, the applicant for both antiretrovirals was Promomed (trade names Mantirivo and Rilpivirine), not the originators.

HIV products: a refusal on formal grounds

According to Vademecum, the applicant's representative asked for the review to be postponed: neither product has yet cleared all the approvals needed for release into civil circulation. The commission declined to postpone, stating that it was obliged to take a decision on the application, and refused inclusion. The applicant was invited to come back once supply can be guaranteed - the publication names the May 2027 session.

The reason lies in patents: cabotegravir and rilpivirine are under protection (the right holders are ViiV Healthcare and Janssen Pharmaceutica respectively). For cabotegravir, the Moscow Region Commercial Court granted a compulsory licence claim on 20 October, but the judgment has not entered into force. For rilpivirine, as the company's representative told the session (as reported by Pharmvestnik), the application has been considered by the governmental commission and the decision is awaiting signature. For context see our review 'Compulsory licences as a market access factor'.

The practical takeaway is broader than this case. Presence in civil circulation and a confirmed ability to supply work as an entry filter regardless of who the applicant is - an originator or a Russian manufacturer of a generic. A marketing authorisation alone is not enough.

Haemophilia A: efanesoctocog alfa

Efanesoctocog alfa (Altuvoct, Sobi) is a coagulation factor VIII administered once a week. The product was registered in Russia on 1 June 2026 (State Register of Medicines) and has been on the procurement list of the Circle of Kindness fund since August 2025. The application sought inclusion in the VED list and the 14 High-Cost Nosologies programme. According to Vademecum, inclusion was supported at the session by specialists of the National Medical Research Centre for Haematology and by the All-Russian Haemophilia Society. The commission did not back the application; the media cite two factors: the product is only in the draft of the updated clinical guidelines, which has been sent back for revision (GxP News, Pharmvestnik), and the cost of therapy is higher than that of the products already used in haemophilia A (Vademecum, Pharmvestnik, GxP News). The wording of the grounds and the vote count will be seen in the minutes.

Why the November session is the first of a cycle, not the last

Under the Rules for forming the lists (Government Resolution No. 871), applications are filed by the 10th day of the first month of a quarter, sessions are held by the 10th day of the second month of the following quarter, and the Ministry of Health submits the draft VED list to the Government no later than 15 October. Applications filed by 10 October and reviewed in November therefore fall into the next cycle: as Pharmvestnik notes, the sessions from November 2026 to August 2027 shape the changes that will apply from 2028.

In our reviews of 15 August and 12 September 2026 we wrote that the filing window closing on 10 October fed into the 2027 list. That was inaccurate; the texts have been corrected. Three filing windows remain for the 2028 list: 10 January, 10 April and 10 July 2027.

The 2027 list: where the document stands

The Ministry of Health published the draft Government directive amending Directive No. 3867-r on 28 September 2026. It proposes adding to the VED list all 12 INNs recommended by the commission in 2026: budesonide + salbutamol (February), sonidegib and pazufloxacin (April) and the nine from August - mosunetuzumab, belumosudil, dantrolene, ertugliflozin, encorafenib, binimetinib, trastuzumab deruxtecan, ravidasvir and verenafusp alfa (the last also for the 14 High-Cost Nosologies programme). The media counted 13 new INNs in the draft, including cavutilide. That is not a new inclusion: the product is already on the list under its chemical name, and the commission minutes of 7 August add the international nonproprietary name assigned by the WHO. Pioglitazone appears in the draft on a different basis (a new A10BG position): as a single-component product from a combination already on the list, under paragraph 6(2) of the Rules.

As of 11 November 2026 the directive has not been signed. The draft provides for entry into force two months after official publication; in the last cycle Directive No. 3867-r was signed on 18 December 2025 and came into force on 24 February 2026. If the calendar repeats itself, the new positions will take effect not on 1 January but towards the end of February 2027 - worth factoring into plans for registering maximum ex-factory prices and for first-quarter tenders.

The condition attached to trastuzumab deruxtecan has been met: the label was amended on 14 October 2026 and now carries a single indication - HER2-positive unresectable or metastatic breast cancer after anti-HER2 therapy. The deadline for the instruction to consider removing 11 INNs expired on 10 November; no outcome has been announced publicly, and the draft directive of 28 September contains none of these removals - the positions concerned are either untouched or retained in the restated wording.

What is being prepared in the rules

In early November, at the National Healthcare congress, Deputy Minister of Health Sergey Glagolev said the Ministry is drafting amendments to Resolution No. 871. Four directions were named: inclusion by individual indication - for countable, mostly hospital products with a high budget burden; re-assessment when new data emerge or indications are expanded; the ability to revise prices registered long ago; and mandatory inclusion of widely used products that remain outside the list. These are statements of intent: no draft text has been published, and it is too early to speak of timing.

Three takeaways for those preparing dossiers for the 2027 windows. First: confirmation of release into circulation and of the ability to supply should be in hand before filing, not by the session. Second: a product's status in the clinical guidelines in force is best settled before filing - the commission does not treat draft guidelines as a document in force. Third: for products with broad labels, the 'narrow' inclusion model first used in August is highly likely to become part of the rules - an indication-based scenario is worth building into the dossier now.

Sources

Agenda of the Ministry of Health commission session of 10 November 2026 (minzdrav.gov.ru, published 28 October 2026); results of the documentary review of third-quarter 2026 proposals (minzdrav.gov.ru, 20 October 2026); draft Government directive amending Directive No. 3867-r (minzdrav.gov.ru, 28 September 2026); minutes of the commission sessions of 5 and 7 August 2026; Government Resolution No. 871 of 28 August 2014 (paragraphs 4.1, 6(2), 13, 31); State Register of Medicines (registration data for Altuvoct and Enhertu); Vademecum (29 September, 29 October, 8 and 10 November 2026); Pharmvestnik (28 September, 3 and 10 November 2026); GxP News (28 September and 10 November 2026); Kommersant (October 2026).

This material is for information purposes only and does not constitute legal advice. Decisions on the inclusion of medicines in reimbursement lists are made by the authorised state bodies.

Questions on market access in Russia and the EAEU? Talk to the WIT Pharma team. Full texts of the documents mentioned are available in the key regulations section.